Table 3. . Logistic regression results for association of coenzyme Q10 with the resolution of statin-associated muscle symptoms.

Variables	Odds ratio (95% CI)	p-value
Model 1 (unadjusted)
Coenzyme Q10 use	0.75 (0.41–1.38)	0.357

Model 2† (adjusted)
Coenzyme Q10 use	0.84 (0.45–1.55)	0.568
Hypertension	1.29 (0.87–1.90)	0.210
Obesity	1.35 (0.81–2.24)	0.257
Smoking	1.13 (0.75–1.71)	0.555
Lovastatin vs atorvastatin	4.50 (1.77–11.43)	0.011
Pravastatin vs atorvastatin	1.42 (0.69–2.94)	0.670
Rosuvastatin vs atorvastatin	1.42 (0.80–2.53)	0.602
Simvastatin vs atorvastatin	1.35 (0.82–2.22)	0.407
Other statin vs atorvastatin‡	1.52 (0.44–5.26)	0.897
Family history of heart disease	0.83 (0.56–1.22)	0.343

Model 3§ (adjusted)
Coenzyme Q10 use	0.82 (0.45–1.51)	0.522
Smoking	1.09 (0.73–1.63)	0.670
Obesity	1.39 (0.84–2.29)	0.203
Family history of muscle disease	1.51 (0.64–3.59)	0.350

Bold p-values indicate p < 0.05.

^†Adjusted for the five variables that were statistically significant in the original study for an association with SAMS [15].

^‡Other statins include cerivastatin, fluvastatin, and pitavastatin.

^§Adjusted for the three variables that were significantly different between Coenzyme Q10 users and non-users in Table 1.

SAMS: Statin-associated muscle symptoms.